Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension

Area of Science:

• Neonatal Medicine
• Pulmonary Hypertension Research
• Pharmacology

Background:

• Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition in neonates.
• Inhaled nitric oxide (iNO) emerged as a key therapeutic agent following pivotal 1990s trials.
• iNO received FDA approval in 1999 for treating PPHN.

Purpose of the Study:

• To review the historical development and clinical application of inhaled nitric oxide (iNO).
• To discuss the clinical features of pulmonary hypertension (PH) in neonates.
• To evaluate the safety and benefits of iNO in neonatal PH management.

Main Methods:

• Literature review of pivotal trials and clinical studies on iNO.
• Analysis of historical data regarding iNO's approval and use.
• Synthesis of current understanding of neonatal PH and iNO's role.

Main Results:

• Inhaled nitric oxide is the only FDA-approved pulmonary vasodilator for PPHN.
• Selective pulmonary vasodilation with iNO is safe in term and near-term neonates with PPHN.
• Targeted iNO use can be beneficial in less mature neonates with pulmonary hypertension.

Conclusions:

• Inhaled nitric oxide remains a cornerstone therapy for PPHN.
• The application of iNO in neonatal pulmonary hypertension requires careful consideration of gestational age and specific clinical context.
• Continued research and understanding of iNO's mechanisms and applications are important.